Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer | Zendy

Alok A. Khorana | Zendy; Gerald A. Soff | Zendy; Ajay K. Kakkar | Zendy; Saroj VadhanRaj | Zendy; Hanno Riess | Zendy; Ted Wun | Zendy; Michael B. Streiff | Zendy; David García | Zendy; Howard A. Liebman | Zendy; Chandra P. Belani | Zendy; Eileen M. O’Reilly | Zendy; Jai N. Patel | Zendy; Habte A. Yimer | Zendy; Peter Wildgoose | Zendy; Paul Burton | Zendy; Ujjwala Vijapurkar | Zendy; Simrati Kaul | Zendy; John W. Eikelboom | Zendy; Robert D. McBane | Zendy; Kenneth A. Bauer | Zendy; Nicole M. Kuderer | Zendy; Gary H. Lyman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

Author(s) -

Alok A. Khorana,

Gerald A. Soff,

Ajay K. Kakkar,

Saroj VadhanRaj,

Hanno Riess,

Ted Wun,

Michael B. Streiff,

David García,

Howard A. Liebman,

Chandra P. Belani,

Eileen M. O’Reilly,

Jai N. Patel,

Habte A. Yimer,

Peter Wildgoose,

Paul Burton,

Ujjwala Vijapurkar,

Simrati Kaul,

John W. Eikelboom,

Robert D. McBane,

Kenneth A. Bauer,

Nicole M. Kuderer,

Gary H. Lyman

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1814630

Subject(s) - medicine , deep vein , pulmonary embolism , ambulatory , hazard ratio , rivaroxaban , thrombosis , randomization , population , surgery , placebo , randomized controlled trial , number needed to treat , relative risk , confidence interval , warfarin , alternative medicine , environmental health , pathology , atrial fibrillation

Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is uncertain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research